PillCall’s servers are set up and running. PillCall’s iPhone app has been approved and is on the App Store. PillCall has three working prototype caps, perfectly capable of being sold for $129 each, but to be used for marketing purposes, Getting to 100 million caps in use will require a substantial marketing push, not to mention a substantial upgrade to the size of our assembly lines to make the caps themselves. The cap design also has room for improvement and a road map is in place for achieving faster and more reliable assemblies with fewer components.
Pharmaceuticals in the US is a $1.4 trillion market, growing at 6% annually with 2 billion pill bottles and caps sold annually.
Initial focus is the 150M Americans who regularly take medicine, 50% of whom fail to comply with their prescriptions.
Customers acquired via retail placement, impulse buying, and word-of-mouth.
Smart bottle startups such as Pillsy, AdhereTech, Jini Health and others, which are focused on smartphone-aided medication reminders using BlueTooth or NFC communication directly with smartphones. PillCall instead uses WiFi without the need for a smartphone. PillCall’s key differentiators include: a retail focus to obtain sticking power with consumers, combined with the tried-and-true subscription model, simple yet direct integration with the SMS text message infrastructure, and medication-agnostic disinterest to engender skeptical consumers’ trust and commitment.
Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
---|---|---|---|---|---|
Revenue | $12,000 | $1,320,000 | $72,600,000 | $319,440,000 | $1,756,920,000 |
EBIT | $(238,000) | $924,000 | $50,800,000 | $239,580,000 | $1,370,397,600 |
Have questions about investing in PillCall? Reach out below.